These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 30531179

  • 1. Anti-IgE therapy for asthma: an audit at atertiary care centre in Saudi Arabia.
    Weheba IM, Abdelsayed AM, Arnaout RK, Zeitouni MO, Mobaireek KF, AlHarthi TB, Mobeireek AF.
    Ann Saudi Med; 2018; 38(6):439-444. PubMed ID: 30531179
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Eligibility for treatment with omalizumab in Italy and Germany.
    Buhl R, Marco AG, Cohen D, Canonica GW.
    Respir Med; 2014 Jan; 108(1):50-6. PubMed ID: 24315468
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Omalizumab in patients with severe asthma: the XCLUSIVE study.
    Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, Rottbauer W, Kroegel C.
    Clin Respir J; 2012 Oct; 6(4):215-27. PubMed ID: 21740532
    [Abstract] [Full Text] [Related]

  • 10. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
    Özgür ES, Özge C, Ïlvan A, Naycı SA.
    J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
    [Abstract] [Full Text] [Related]

  • 11. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.
    Kornmann O, Watz H, Fuhr R, Krug N, Erpenbeck VJ, Kaiser G.
    Pulm Pharmacol Ther; 2014 Aug; 28(2):149-53. PubMed ID: 24657236
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Omalizumab: NICE to USE you, to LOSE you NICE.
    Bush A, Pavord ID.
    Thorax; 2013 Jan; 68(1):7-8. PubMed ID: 23229814
    [No Abstract] [Full Text] [Related]

  • 16. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.
    Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K.
    Allergy; 2016 May; 71(5):593-610. PubMed ID: 26644231
    [Abstract] [Full Text] [Related]

  • 17. Omalizumab (anti-IgE) therapy increases blood glucose levels in severe persistent allergic asthma patients with diabetes mellitus: 18 month follow-up.
    Yalcin AD, Gorczynski RM, Cilli A, Strauss L.
    Clin Lab; 2014 May; 60(9):1561-4. PubMed ID: 25291953
    [Abstract] [Full Text] [Related]

  • 18. Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria.
    Hew M, Gillman A, Sutherland M, Wark P, Bowden J, Guo M, Reddel HK, Jenkins C, Marks GB, Thien F, Rimmer J, Katsoulotos GP, Cook M, Yang I, Katelaris C, Bowler S, Langton D, Wright C, Bint M, Yozghatlian V, Burgess S, Sivakumaran P, Yan KY, Kritikos V, Peters M, Baraket M, Aminazad A, Robinson P, Jaffe A, Powell H, Upham JW, McDonald VM, Gibson PG.
    Clin Exp Allergy; 2016 Nov; 46(11):1407-1415. PubMed ID: 27377155
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.